19 April 2018: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to announce that it is the lead industry participant in a new £1.5 million grant award from the UK’s innovation agency, Innovate UK, to advance development of its hRPC stem cell therapy candidate for blindness-causing degenerative diseases of the retina.

Read more…

10 April 2018: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to announce that Dr Richard Beckman has joined the Company as Chief Medical Officer.  He replaces Dr Julian Howell who has left the Company to pursue another opportunity.

Read more…

 

26 March 2018: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to provide an update across its research and development programmes.

Read more…

Positive pre-clinical data published using ReNeuron’s CTX cells in artificial nerve tissue generated as part of a grant-funded collaboration

26 January 2018: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to announce the publication of new positive data in a pre-clinical model of nerve injury which demonstrated comparable nerve regeneration compared to standard of care treatment and a stronger muscle function response.

Read more …

Positive long-term data from Phase II stroke disability clinical trial accepted for a late-breaking podium presentation at the American Heart Association International Stroke Conference 2018

26 January 2018: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to announce that positive long-term data from the Phase II clinical trial (PISCES II) of its CTX cell therapy candidate for stroke disability was accepted for a podium presentation given yesterday at the American Heart Association International Stroke Conference 2018 (“ISC 2018”),  taking place this week in Los Angeles.

Read more…

To view the presentation please click here.

23 January 2018: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, announced on 5 January 2018 details of a proposed of the existing ordinary share capital of the Company. The Board is pleased to announce that at today’s General Meeting of the Company, Shareholders approved all of the Resolutions set out in the Circular.

Read more …

 

11 January 2018: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, today makes the following announcement in connection with the proposed Share Capital Reorganisation of the existing ordinary share capital of the Company announced on 5 January 2018

Read more…

 

ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to announce a proposed Share Capital Reorganisation of the existing ordinary share capital of the Company.

Read more…

To view the circular please click here.

14 December 2017: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to announce its interim results for the six months ended 30 September 2017.

Read more…

To view the Interim Results Presentation slide deck please click here.

To log on to view the webcast of the analyst presentation please click here.

FDA approves ReNeuron’s IND application to commence a Phase IIb clinical trial in the US in stroke disability

14 December 2017: ReNeuron Group plc (AIM: RENE), a global leader in the development of cell-based therapeutics, is pleased to announce that the FDA has given regulatory approval for the Company to commence a Phase IIb clinical study in the US with its CTX cell therapy candidate for stroke disability.

Read more…